A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

• Status: Not yet recruiting
• Trial end date: 2026-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with a multiple myeloma (MM)-targeting monoclonal antibody capable of inducing antibody-dependent cellular toxicity (ADCC) in participants with relapsed or refractory (R/R) MM who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genentech, Inc.
• Treatments: Daratumumab

Criteria

Inclusion Criteria:

• Life expectancy of at least 12 weeks

• Measurable disease, as defined by the protocol

• Participants must have received a minimum of 3 prior lines of therapy, including at least one PI, one IMiD, and an anti-CD38 monoclonal antibody

• Best response of stable disease or better with at least one prior anti-CD38 monoclonal antibody containing line of treatment

Exclusion Criteria:

• Any anti-cancer therapy within 3 weeks prior to initiation of study treatment, with exceptions defined by the protocol

• Prior allogeneic stem cell or solid organ transplantation

• Autologous stem cell transplantation within 100 days prior to initiation of study treatment

• Significant cardiovascular disease

• Known clinically significant liver disease

• Active or history of autoimmune disease or immune deficiency

• Known active infection requiring IV anti-microbial therapy within 14 days prior to first study drug administration

• Primary or secondary plasma cell leukemia

• Current CNS involvement by MM

• Other protocol defined inclusion/exclusion criteria may apply